MDP vs. ICC, OGI, RIV, LEAF, CRDL, RX, HLS, TGOD, NINE, and SUGR
Should you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include ICC Labs (ICC), Organigram (OGI), RIV Capital (RIV), Leaf Mobile (LEAF), Cardiol Therapeutics (CRDL), BioSyent (RX), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), and SugarBud Craft Growers (SUGR). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Medexus Pharmaceuticals vs.
Medexus Pharmaceuticals (TSE:MDP) and ICC Labs (CVE:ICC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Medexus Pharmaceuticals has a net margin of 3.25% compared to ICC Labs' net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 11.07% beat ICC Labs' return on equity.
8.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Medexus Pharmaceuticals currently has a consensus target price of C$5.49, suggesting a potential upside of 107.86%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Medexus Pharmaceuticals is more favorable than ICC Labs.
In the previous week, Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled ICC Labs'average media sentiment score.
ICC Labs received 123 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Medexus Pharmaceuticals an outperform vote while only 65.84% of users gave ICC Labs an outperform vote.
Medexus Pharmaceuticals has higher revenue and earnings than ICC Labs. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.
Summary
Medexus Pharmaceuticals beats ICC Labs on 13 of the 16 factors compared between the two stocks.
Get Medexus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medexus Pharmaceuticals Competitors List
Related Companies and Tools
This page (TSE:MDP) was last updated on 5/22/2025 by MarketBeat.com Staff
